The SGLT-2 inhibitor ertugliflozin reduces the risk of hospitalisation for heart failure (HHF) by 30% compared to placebo in patients with type 2 diabetes and atherosclerotic disease, research shows . The eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV), presented at the virtual American Diabetes Association 2020 virtual Scientific Sessions, included data from ...
SGLT-2 inhibitor ertugliflozin delivers on heart failure
By Mardi Chapman
24 Jun 2020